Overview

Therapeutic Strategies to Overcome ALK Resistance in Cancer, Volume 13, presents current strategies to improve and prolong clinical benefit in ALK driven cancers. Most patients with ALK-driven cancer are sensitive to tyrosine kinase inhibitor (TKI) therapy, but resistance invariably develops. This book discusses topics such as structure and function of ALK, ALK rearranged lung cancer, resistance mechanisms to ALK TKI tumors, and novel therapeutic strategies to enhance crizotinib anti-tumor efficacy in ALCL. Additionally, it encompasses information on drug combinations to enhance ALK TKI anti-tumor efficacy in neuroblastoma and future perspectives in the field. This book is a valuable resource for cancer researchers, clinicians and several members of biomedical field who need to understand more about how to fight ALK resistance in cancer treatment.

Full Product Details

Author:   Luc Friboulet (ERC Principal Investigator and INSERM Team Leader, Gustave Roussy Cancer Campu, France) ,  Luc Friboulet (ERC Principal Investigator and INSERM Team Leader, Gustave Roussy Cancer Campu, France) ,  Luc Friboulet (ERC Principal Investigator and INSERM Team Leader, Gustave Roussy Cancer Campu, France) ,  Luc Friboulet (ERC Principal Investigator and INSERM Team Leader, Gustave Roussy Cancer Campu, France)
Publisher:   Elsevier Science Publishing Co Inc
Imprint:   Academic Press Inc
Weight:   0.630kg
ISBN:  

9780128217740

ISBN 10:   012821774
Pages:   216
Publication Date:   14 January 2021
Audience:   Professional and scholarly ,  Professional & Vocational
Format:   Hardback
Publisher's Status:   Active
Availability:   Manufactured on demand  
We will order this item for you from a manufactured on demand supplier.

Table of Contents

1. Structure and function of ALK 2. ALK rearranged lung cancer: Treatment and outcome 3. Systemic treatments other than TKI: reflections on chemotherapy, immunotherapy and antiangiogenic agents in ALK-driven NSCLC 4. Management of ALK positive patients with tumors other than lung cancer (ALCL, neuroblastoma, Inflammatory Myofibroblastic Tumor) 5. Resistance mechanisms to ALK TKIs in lung cancer: from single to compound mutations, from tissue to liquid biopsy 6. Resistance mechanisms to ALK TKI in tumors other than lung cancer 7. Therapeutic strategies to overcome ALK resistance in lung cancer 8. Novel Therapeutic strategies to enhance crizotinib anti-tumor efficacy in ALCL: use of ACD 9. Drug combinations to enhance ALK TKI anti-tumor efficacy in Neuroblastoma 10. State of the art and future perspectives

Reviews

"""This book is a valuable resource for cancer researchers, clinicians and several members of biomedical field who need to understand more about how to fight ALK resistance in cancer treatment."" --Anticancer Research"

This book is a valuable resource for cancer researchers, clinicians and several members of biomedical field who need to understand more about how to fight ALK resistance in cancer treatment. --Anticancer Research

Author Information

Luc Friboulet, PhD, is ERC Principal Investigator and INSERM team leader at Gustave Roussy cancer campus. He studies the tumor adaptation to kinase inhibitors. Linked to a clinical trial named MATCH-R allowing collection of repeated biopsies in patients treated with ALK, ROS1, RET, EGFR, BRAF, FGFR inhibitors Dr. Friboulet characterizes the resistance mechanisms and establishes new laboratory models.

Tab Content 6

Author Website:  

Customer Reviews

Recent Reviews

No review item found!

Add your own review!

Countries Available

All regions